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Abstract
The era of personalized medicine for cancer therapeutics has taken an important step forward in making accurate
prognoses for individual patients with the adoption of high-throughput microarray technology. However, microarray
technology in cancer diagnosis or prognosis has been primarily used for the statistical evaluation of patient populations,
and thus excludes inter-individual variability and patient-specific predictions. Here we propose a metric called clinical
confidence that serves as a measure of prognostic reliability to facilitate the shift from population-wide to personalized
cancer prognosis using microarray-based predictive models. The performance of sample-based models predicted with
different clinical confidences was evaluated and compared systematically using three large clinical datasets studying the
following cancers: breast cancer, multiple myeloma, and neuroblastoma. Survival curves for patients, with different
confidences, were also delineated. The results show that the clinical confidence metric separates patients with different
prediction accuracies and survival times. Samples with high clinical confidence were likely to have accurate prognoses from
predictive models. Moreover, patients with high clinical confidence would be expected to live for a notably longer or
shorter time if their prognosis was good or grim based on the models, respectively. We conclude that clinical confidence
could serve as a beneficial metric for personalized cancer prognosis prediction utilizing microarrays. Ascribing a confidence
level to prognosis with the clinical confidence metric provides the clinician an objective, personalized basis for decisions,
such as choosing the severity of the treatment.
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Introduction
Not all individuals respond to drug treatment in the same way.
Accordingly, the development of personalized therapeutic regi-
mens optimized for individual patients represents a major goal of
21
st-century medicine [1]. Modern tools are being utilized to assist
physicians in effectively treating patients as individuals and
providing personalized drug intervention.
Inter-individual variation in response to drug treatment is
strongly influenced by a patient’s physiological state at the time of
treatment. This state can be characterized by gene expression
profiles [2]. Therefore, microarray technology can guide the
selection of drugs or therapeutic regimens and be employed to
assess the susceptibility of a patient to certain diseases, enabling a
personalized plan for prevention monitoring and treatment [3].
The prospective benefits of microarray technology in clinical
applications have been demonstrated by several landmark studies
[4–7]. Microarray-based predictive models (or genomic signatures)
have shown utility in associating different subgroups of breast
cancer with distinct clinical outcomes [8–13], such as Mamma-
Print
TM [4,5], a milestone in microarray-based prognosis for
breast cancer [14].
The development of a microarray-based predictive model for
tumor classification typically involves two sequential steps [4,15–
17]. First, the model is developed based on a training set of
patients with known class labels (e.g., tumor status) and gene
expression data. Next, the training model is validated using a
validation set that contains patients with known class labels. The
validity of the training model in performance on the validation set
has been the focus of ‘class prediction’ research. To ensure the
training model can be used in real-world clinical applications, it
was suggested that the model must be assessed on a large number
of independent samples in this external validation process [18].
It is important to note that the aforementioned external
validation strategy assesses the performance of a training model
using a population defined by the validation set. The average
performance (e.g., specificity, sensitivity) over the population is
used to assess whether the model can be a reliable diagnostic or
prognostic test. This strategy is performed under the assumption
that the model performs equally for everyone without considering
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based on a population of patients cannot ensure its predictive
ability for individual patients, which might result in potentially
unreliable diagnoses or prognoses in the real-world application.
This one-size-fits-all strategy needs to be modified from popula-
tion-wide to personalized medicine in microarray data-based
applications.
We propose a metric called clinical confidence that measures
the model’s reliability in prediction performance on an individual
basis. Clinical confidence can be useful in determining appropriate
treatments; for example, patients with high confidence and poor
prognosis may be given more rigorous treatments. Additionally,
patients with lower clinical confidences may be prime candidates
for further evaluation of their conditions with alternative methods.
The accuracy of the clinical confidence metric was investigated on
three large clinical datasets with total of six clinical endpoints [19].
Specifically, we first divided each dataset into two, i.e., the
training and validation set. To mimic real-world clinical scenarios,
we made the validation set that contains only the patients whose
microarray data were generated at a later date than those in the
training set. We derived the clinical confidence from the training
model, followed by the assessment of its correlation with prediction
accuracy for prognosis and the survival time of the patients in the
validation set. To the best of our knowledge, this is the first
attempt to provide a measure of confidence for individual patients
in microarray-based ‘‘class prediction’’ research, which is an
important step forward in personalized medicine.
Materials and Methods
Datasets
Three large-scale, clinical cancer datasets were used in this
study: breast cancer (BR) [20], multiple myeloma (MM) [21], and
neuroblastoma (NB) [22]. A concise summary of the datasets is
given in Table 1. More detailed information of these datasets can
be found in the main paper of the second phase of MicroArray
Quality Control project (MAQC-II) [19].
Each dataset has two clinical endpoints related to cancer
prognosis (including survival data) or treatment: BR-pCR and BR-
erpos in the treatment response dataset, NB-EFS and MM-EFS in
the event-free survival dataset, and NB-OS and MM-OS in the
overall survival dataset (Table 1). These three clinical datasets
were studied in the MAQC-II project led by the FDA [19]. To
emulate a real-world clinical scenario in applying genomic
signatures, two independent populations of patients for each of
the three clinical datasets were defined by the MAQC Consortium
as the training and validation sets using a chronological approach
where the samples in the validation sets were generated at a later
date than those in the training sets. The sample sizes for the
training sets varied between 130 and 340, and the ratio of positive
events to negative events ranged from 0.18 to 1.60; meanwhile, the
sample sizes in the validation sets ranged from 100 to 214, and the
ratio of positive events to negative events varied between 0.14 and
1.56.
Two positive and two negative control endpoints were also used
in this study. The positive control endpoints, i.e., NB-PC and
MM-PC, were derived from the NB and MM datasets separately,
with the samples denoted by the gender. For the two negative
control endpoints, i.e., NB-NC and MM-NC (which correspond to
the NB and MM datasets, respectively), the sample labels (i.e.,
positive or negative events) were randomly generated. Using these
two controls allow us to assess the performance of the clinically
relevant endpoints against the expected maximum and minimum
performance provided by the controls.
Clinical confidence
The clinical confidence measures the confidence of a sample
being assigned to a specific class by a predictive model.For sample i,
its clinical confidence metric (Ci) is the confidence level of a sample
in being correctly assigned by a predictive model and is defined as:
Ci~
x1 jj = x1 jj z x2 jj ðÞ x1 jj w x2 jj
x2 jj = x1 jj z x2 jj ðÞ x1 jj ƒ x2 jj

ð1Þ
where x1 and x2 are the similarity measures between sample i and
samples in class 1 and class 2, respectively. The similarity measure
varies according to classifiers used. Two well-studied classifiers for
gene expression data were employed in this study, i.e., Nearest-
Centroid classification rule (NC) [4] and k-nearest neighbors (kNN,
k=5) [23]. For the NC classifier, x1 and x2 were defined as the
correlation coefficients of the unknown sample to the centroids of
class 1 and class 2, respectively. The centroid is defined as vectors of
the average expression values. For the kNN classifier, x1 and x2 are
defined to be the number of nearest neighbors to the unknown
sample belonging to class 1 and class 2, respectively.
Ci values range from 0.5 and 1 in which a value of 0.5 indicates
that the prediction is due to chance. Increasingly larger Ci values
correspond to increasingly higher prediction confidence. For the
sake of simplicity, all of the analysis was based on three confidence
levels: low confidence (LC; 0.5#Ci#0.6), medium confidence
(MC; 0.6,Ci#0.8) and high confidence (HC; 0.8,Ci#1.0).
Statistical analysis
The general analysis workflow is depicted in Figure 1;
additional details are provided in Methods S1. The analysis
protocol starts by developing a best classifier based on the training
set, and ends by predicting the validation set. The predicted class
and corresponding clinical confidences are recorded in matrices L
and C, respectively. To ensure the statistical validity, the procedure
is repeated 500 times, resulting in 500 different classifiers from the
training sets and 500 predictions for the validation set. The
performance of both training models and predictions is assessed
using Matthews correlation coefficient (MCC) [24,25].
A permutation test was also employed to compare classifier
prediction accuracy versus chance [26,27]. In each permutation,
the analysis protocol shown in Figure 1 was repeated with the
exception that the class labels in the training set were randomized.
In other words, models constructed with randomized training sets
were utilized to predict the validation sets. After 500 repetitions,
the degree of chance correlation and predictability of endpoints
was computed with Cohen’s d [28], which measures the
standardized difference between two means.
Results
The cross-validation performance measured in MCC values for
all the training models along with the average prediction
performance on the validation sets are summarized in Table
S1. The model performance follows the order of NB-PC, MM-PC,
BR-erpos, NB-EFS, NB-OS, BR-pCR, MM-EFS, MM-OS, MM-
NC, and NB-NC. The two positive controls performed best while
the two negative controls perform worst, which is consistent with
expectations from the experiment design.
Clinical confidence positively correlates with the model
prediction performance
We first investigated the model performance on the validation
set for patients falling into different categories of clinical
Predictive Model for Personalized Cancer Prognosis
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shown between the prediction accuracy and the confidence level
for the six clinical and four control endpoints using the kNN
classifier. Among the six clinical endpoints, the BR-erpos dataset
showed the strongest correlation. For the BR-erpos, the average
MCC value predictions with low confidence (LC) was only 0.19,
while the average MCC value markedly increased to approxi-
mately 0.78 as the confidence level approached 1. Thus, compared
to the overall MCC value (0.71) (Table S1), clinical confidence
could successfully account for inter-individual variability in
discriminating patients with lower or higher than average
prediction accuracy.
It is clear that the intrinsic predictability by gene expression
profiles varies for different endpoints, as evidenced by the gradual
decrease in the steepness of model performance for six clinical
endpoints over different confidence intervals (i.e., the slopes in
Figure 2, data was shown in Table S2) and the number of
samples distributed across different confidence regions (i.e., the
marker size in Figure 2). As shown in Figure 3, a positive linear
correlation was observed between the slope obtained from
Table 1. A concise summary of datasets.
Data Set
code
Endpoint
Description Endpoint Code* Sample Size Ratio of events
Microarray Platform
(number of channel)
Training Validation Training Validation
BR Treatment Response BR-pCR 130 100 0.34 (33/97)
{ 0.18 (15/85) Affymetrix U133A (1)
BR-erpos 130 100 1.60 (80/50) 1.56 (61/39)
MM Overall Survival
Milestone Outcome
MM-OS 340 214 0.18 (51/289) 0.14 (27/187) Affymetrix
U133Plus2.0 (1)
Event-free Survival
Milestone Outcome
MM-EFS 340 214 0.33 (84/256) 0.19 (34/180)
NB Overall Survival
Milestone Outcome
NB-OS 246 177 0.32 (59/187) 0.28 (39/138) Agilent NB
Customized Array (2)
Event-free Survival
Milestone Outcome
NB-EFS 246 193 0.65 (97/149) 0.75 (83/110)
Control Positive control NB-PC 246 231 1.44 (145/101) 1.36 (133/98) Agilent NB
Customized Array (2)
MM-PC 340 214 1.33 (194/146) 1.89 (140/74) Affymetrix
U133Plus2.0 (1)
Negative control NB-NC 246 253 1.44 (145/101) 1.30 (143/110) Agilent NB
Customized Array (2)
MM-NC 340 214 1.43 (200/140) 1.33 (122/92) Affymetrix
U133Plus2.0 (1)
*BR - Breast Cancer; MM - Multiple Myeloma; NB - Neuroblastoma; pCR - Pathologic Complete Response; erpos – ER Positive; OS – Overall Survive; EFS – Event-free
Survival; PC – Positive Control; NC – Negative Control.
{Ratio of good to poor prognoses (i.e., good/poor prognoses).
doi:10.1371/journal.pone.0029534.t001
Figure 1. Detailed workflow for correlation analysis of clinical confidence and model performance. Additional details are provided in
Methods S1.
doi:10.1371/journal.pone.0029534.g001
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[28]) of the six clinical and four control endpoints. The predictable
endpoints (e.g., BR-erpos, NB-EFS) tended to have a larger
percentage of patients (represented as the marker size in Figure 2)
in the high confidence regions with high prediction accuracy than
the less predictable endpoints (e.g., MM-EFS, MM-OS). Detailed
information about sample distribution in each confidence region
was given in Table S3. These observations were further verified
using a different pattern recognition method (i.e., NC)( Figures S1
and S2), and also a different sample splitting strategy (80/20
splitting, Figures S4 and S5).
The results demonstrate that a higher inherent predictability of
an endpoint is related to a higher percentage of patients that fall
into higher confidence levels when using microarray-based
predictive models. As the correlation of a genomic signature with
a clinical outcome is rarely perfect, the clinical confidence could be
useful to separate the patients into different groups for whom
specific treatment procedures can be developed.
The relationship of clinical confidence with patient’s
survival time
We also evaluated whether clinical confidence is predictive of
the survival rate for the patients in the validation set. The patients
were divided into two prognosis groups (i.e., good and poor
prognosis) for both NB and MM datasets with endpoints OS
(overall survival) and EFS (event-free survival), respectively
(Methods S1). Figure 4 presents the OS curves for patients
with different clinical confidences for both prognosis groups.
Patients with high clinical confidence exhibited an increased
survival rate in the good prognosis group and a decreased survival
rate in the poor prognosis group, indicating that the clinical
confidence enhanced the accuracy of prognosis derived from the
predictive models. Taking MM-OS as an example, the survival
rate is apparently higher for patients in the good prognosis group
with high confidence (HC) compared to those with low (LC) (log-
rank test p value,0.01) and medium (MC) ones (log-rank test p
value 0.13), especially for each day mark more than 1000 days
(Figure 4). For patients with poor prognosis, more than 80% of
those with low clinical confidence lived as long as 300 days, while
approximately 30% of patients for those with high confidences
survived at that time, respectively. Similar trends were also
observed in the NB-OS dataset.
Figure S3, depicting the EFS curves for patients with different
clinical confidences, demonstrates a similar trend as the OS curves
presented in Figure 4. The positive correlation of clinical
confidence with EFS rate is clearly shown in Figures S3c and
S3d for the patients with good prognosis. However, the
correlation is less significant for patients with poor prognosis
(Figures S3a and S3b). Corresponding results for 80/20
splitting was shown in Figures S6 and S7, and conformed to
those above-mentioned observations.
The results demonstrate that once the patients were grouped
into either good or poor prognosis groups by the predictive
models, the clinical confidence can further characterize the
survival rate of individual patients in each prognosis group.
Discussion
Several population-wide diagnostic/prognostic tests based on
gene expression have been reported [4,6,7]. The population-based
models provide only an average indication for the population with
Figure 2. Prediction MCC as a function of clinical confidence for ten datasets using kNN. The Circle radii are scaled to the percentage of
total samples in the clinical confidence level. The confidence levels are ‘0.6’, ‘0.8’, and ‘1’.
doi:10.1371/journal.pone.0029534.g002
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the linear portion of the confidence-MCC curve, while Cohen’s d represents the inherent predictability of the dataset.
doi:10.1371/journal.pone.0029534.g003
Figure 4. Overall survival (OS) curves for patients with different clinical confidences using kNN, where ‘LC’, ‘MC’, and ‘HC’ denote
‘low confidence (0.6)’, ‘medium confidence (0.8)’, and ‘high confidence (1)’, respectively.
doi:10.1371/journal.pone.0029534.g004
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demonstrated that clinical confidence is both capable of separating
patients that can be more reliably predicted from those that are
less accurately predicted, and predictive of the survival rate for the
patients after they are grouped into different prognostic groups.
Thus, ascribing a confidence level to prognosis with the clinical
confidence metric will provide the clinician a more personalized,
objective basis for decisions when using biomarkers derived from
microarray data.
Specifically, we found that the clinical confidence provided a
better estimation for the survival time when patients were classified
into different prognosis categories based on both 70/30 and 80/20
sample assignments. For patients with good prognosis, higher
clinical confidence was strongly correlated with longer survival
time. Similarly, for patients with poor prognosis, the survival rate
was significantly lower for those with high confidences than for the
others. Taking endpoints MM-EFS and MM-OS as examples,
despite the fact that they are rather difficult to be predicted,
patients with high confidence display a significantly higher or
lower survival rate when they are grouped in accordance with
good or poor prognosis, respectively. Importantly, all patients in
the high confidence group survived to 5000 days (Figure S3c),
demonstrating that clinical confidence is an informative survival
time prognosis tool.
An important aspect of this study is that two positive (NB-PC,
MM-PC) and two negative control (NB-NC, MM-NC) datasets
were involved, which is essential to assess the performance of the
clinically relevant endpoints against the theoretical maximum and
minimum performance provided by the controls. Specifically, the
positive correlation between model performance and clinical
confidence for the two positive control datasets shown in Figure 2
confirmed the potential of clinical confidence to provide a measure
of reliability for personalized medicine, while the negligible impact
of clinical confidence in the two negative control datasets further
limited the possibility of obtaining false positives. Thus, the
inclusion of positive and negative control datasets in such an
analysis would be of great help to ensure the reliability of the
results.
It remains enigmatic why some of the endpoints were more
difficult than others to predict. Figure 2 and Figure 3 compare
predictability across the three datasets and corresponding six
endpoints. Readily predictable endpoints have a high percentage
of patients who fall into the high confidence region. For example,
the percentage of patients that showed high clinical confidence
(74.70%) for the BR-erpos endpoint is much higher than that of
the MM-EFS endpoint (37.51%) (Figure 2), which may indicate
that the BR-erpos endpoint contains a stronger gene expression
signal than MM-EFS does. Additionally, the predictability of the
dataset (Cohen’s d) is directly related with the correlation
coefficient between the confidence level and MCC prediction
performance (Figure 3).
The ability to quantify clinical confidences may greatly enhance
clinical decision-making processes based on microarray-based
prediction models, especially for personalized treatment options.
For example, the models presented here could test for potential
treatment response with the high confidence and low confidence
predictions being used in different ways. Patients with good
prognosis and high confidences are candidates for applying routine
protocols to avoid over-treatment, while rigorous strategies should
be selected for those with poor prognosis and high confidences to
prolong survival time as long as possible. However, for patients in
the low confidence regions, additional evaluation using alternative
methods should be considered.
It is important to note that the strategy proposed in this study
emphasizing the shift from population-based to personalized
cancer prognosis does not negate the importance of population-
based prediction, but rather builds upon its success. If the
performance of a predictive model is not informative, such as seen
in the two negative controls (i.e., MM-NC and NB-NC), the
clinical confidence will not be predictive. Thus, model validation
methods that include cross-validation and independent external
validation are still essential to ensure the validity of microarray-
based predictive models. However, since the population-based
prediction does not provide an accurate assessment for each
patient within the population, clinical confidence offers a means to
measure reliability for individual predictions based on the
population-based prediction.
The benefits of personalized medicine in health care are well
recognized [1]. It allows both the patient and the physician to be
more aware of the benefits and risks of possible treatments and
potential outcomes affected by genetic make-up or other
environmental influences. Thus, informed, tailored, and health-
related decisions can be made for each person [29]. Combining
microarray technology capable of profiling the expression levels of
hundreds of thousands of genes with pattern recognition
techniques has been an important step toward individualized
decision-making [30]. We presented examples applying confidence
assessment to cancer prognosis and survival time prediction for
models developed from microarray data. However, the approach
can be generalized to biomarkers and models built based on data
from other high throughput platforms. Moreover, the concept is
generally applicable for all supervised learning classification
methodologies that can define a clinical confidence.
Supporting Information
Figure S1 Prediction MCC as a function of clinical
confidence for ten datasets using NC. Circle radii are scaled
to the percentage of total samples in the clinical confidence level.
The confidence levels are ‘0.5–0.6’, ‘0.6–0.8’ and ‘0.8–1’,
respectively.
(TIF)
Figure S2 Correlation between slope rate and Cohen’s d
for the NC classifier. The slopes are obtained from regression
analysis based on the linear portion of the confidence-MCC curve,
while Cohen’s d represents the inherent predictability of the
dataset.
(TIF)
Figure S3 Event-free survival (EFS) curves for patients
with different clinical confidences using kNN where
‘LC’, ‘MC’, and ‘HC’ denote ‘low confidence (0.6)’,
‘medium confidence (0.8)’, and ‘high confidence (1)’,
respectively.
(TIF)
Figure S4 Prediction MCC as a function of clinical
confidence for ten datasets using 80/20 splitting and
kNN. The Circle radii are scaled to the percentage of total
samples in the clinical confidence level. The confidence levels are
‘0.6’, ‘0.8’, and ‘1’.
(TIF)
Figure S5 Correlation between slope rate and Cohen’s d
for the kNN classifier based on 80/20 sample assign-
ment. The slopes are obtained from regression analysis based on
the linear portion of the confidence-MCC curve, while Cohen’s d
represents the inherent predictability of the dataset.
(TIF)
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different clinical confidences using 80/20 splitting and
kNN, where ‘LC’, ‘MC’, and ‘HC’ denote ‘low confidence
(0.6)’, ‘medium confidence (0.8)’, and ‘high confidence
(1)’, respectively.
(TIF)
Figure S7 Event-free survival (EFS) curves for patients
with different clinical confidences using 80/20 splitting
and kNN, where ‘LC’, ‘MC’, and ‘HC’ denote ‘low
confidence (0.6)’, ‘medium confidence (0.8)’, and ‘high
confidence (1)’, respectively.
(TIF)
Table S1 MCC performance for training and validation sets.
(DOCX)
Table S2 Slope and Cohen’s d for each dataset.
(DOCX)
Table S3 Percentage of patients in low confidence (LC), medium
confidence (MC) and high confidence (HC) regions.
(DOCX)
Methods S1 Construction of the best classifier and calculate the
correlation between clinical confidence and survival rate.
(DOC)
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